

SHORTER IS SMARTER

SUMMARY OF APPROPRIATE USE OF SHORT-COURSE ANTIBIOTICS IN COMMON INFECTIONS

Condition	Short duration	Available evidence	Mortality	Length of stay	Clinical success rate	Relapse rate	Adverse events	Tufts Medical Center Antimicrobial Stewardship Team Advice
Acute exacerbation of chronic bronchitis (AECB) or chronic pulmonary obstructive disease (COPD)	5 days	GOLD guideline ¹ >20 RCTs (N=11,008) ^{24,25}	No difference in mortality between groups ²	<i>Limited/insufficient data</i>	No difference in clinical improvement between groups ¹	No difference in one-year exacerbation rate between groups ²	No difference in adverse events between groups ²	Clinicians should limit antibiotic treatment duration to 5 days when managing patients with COPD exacerbations and acute uncomplicated bronchitis who have clinical signs of bacterial infection (presence of increased sputum purulence in addition to increased dyspnea, and/or increased sputum volume). ¹
Community-acquired pneumonia (CAP)	3-5 days	IDSA/ATS guideline ¹ 14 RCTs (N=8,732) ¹	Lower mortality in short-course group ¹	No difference in length of ICU stay between groups ³	No difference in clinical improvement between groups ¹	No difference in relapse rates between groups ^{4,5}	Fewer adverse events in short-course group ¹	Clinicians should prescribe antibiotics for CAP for a minimum of 5 days. Extension of therapy after 5 days of antibiotics should be guided by validated measures of clinical stability, which include resolution of vital sign abnormalities, ability to eat, and normal mentation. ¹
Uncomplicated urinary tract infection (UTI): bladder infection in afebrile men and women	3-5 days or single-dose, depending on antibiotic selected	IDSA/ESCMID guideline ¹ 3 recent RCTs ¹	<i>Limited/insufficient data</i>	<i>Limited/insufficient data</i>	No difference in clinical improvement between groups except in patients with complicated UTI ¹	No difference in rate of recurrent UTI within 30 days ¹	No difference in adverse events between groups ^{6,7}	Clinicians should prescribe short-course antibiotics with either nitrofurantoin for 5 days, trimethoprim-sulfamethoxazole (TMP-SMX) for 3 days, or fosfomycin as a single dose. ¹
Complicated UTI: febrile UTI, pyelonephritis, CAUTI	5-7 days	IDSA/ESCMID guideline ¹ 10 RCTs (N=2,945) ¹	<i>Limited/insufficient data</i>	<i>Limited/insufficient data</i>	No difference in clinical improvement between groups ^{1,6,8,39}	No difference in rate of recurrent infections ³⁹	No difference in adverse events between groups ^{9,10,39}	For pyelonephritis or febrile UTI in both males and females, duration of therapy will vary based upon agent and antibiotic susceptibilities. Give fluoroquinolones for 5 days or non-fluoroquinolone antibiotic for 7 days. ^{9,10,11}
Nonpurulent cellulitis	5-6 days	IDSA guideline ¹ NICE guideline ¹ 4 RCTs (N=1,412) ¹	<i>Limited/insufficient data</i>	<i>Limited/insufficient data</i>	No difference in clinical improvement between groups ¹	<i>Limited/insufficient data</i>	Gastrointestinal adverse events were less frequent or similar with 6-day tedizolid than 10-day linezolid ¹¹	In patients with nonpurulent cellulitis, clinicians should use a 5- to 6-day course of antibiotics active against streptococci, particularly for patients able to self-monitor and who have close follow-up with primary care. ¹
Debrided diabetic foot osteomyelitis	21 days	1 RCT (N=93) ³³	<i>Limited/insufficient data</i>	<i>Limited/insufficient data</i>	No difference in clinical improvements in between groups	<i>Limited/insufficient data</i>	No difference in adverse events	In a randomized controlled pilot trial, a postdebridement systemic antibiotic therapy course for diabetic foot osteomyelitis of 3 weeks gave similar (and statistically noninferior) incidences of remission and adverse events to a course of 6 weeks ³³

RCT: Randomized Clinical Trial

*Direct recommendation from ACP Guidelines

**Direct recommendation from the IDSA

Compiled from ACP and other literature

Condition	Short duration	Available evidence	Mortality	Length of stay	Clinical success rate	Relapse rate	Adverse events	Tufts Medical Center Antimicrobial Stewardship Team Advice
Ventilator-associated pneumonia (VAP)	7 days	IDSA guideline ¹² 2 systematic reviews of RCTs (N=626) ¹² 1 observational study ¹²	No difference in mortality between groups ^{12,13,14}	No difference in length of hospital or ICU stay between groups ¹²	No difference in clinical improvement between groups ¹²	No difference in recurrent pneumonia between groups ¹²	No difference in adverse events between groups ¹²	For patients with VAP, clinicians should use a 7-day course of antimicrobial therapy. There is no longer a recommendation to use a longer duration for specific organisms.** There exist situations in which a shorter (5-day) duration of antibiotics may be indicated, depending upon the rate of improvement of clinical, radiologic and laboratory parameters. ^{12,15}
Intra-abdominal infection	4- 7 days	2 RCTs (N=766) ¹	No difference in mortality between groups ^{16,18,19}	No difference in length of hospital stay between groups ^{16,18,19}	No difference in clinical improvement or improved in shorter-course group ^{16,18,19}	No difference in recurrent infections or 30-day readmission rate between groups ^{16,17,18}	<i>Limited/insufficient data</i>	Antimicrobial therapy of established infection should be limited to 4-7 days. Evidence supports that if source control is achieved, antimicrobial therapy is advised for 4 days. If source control has not been achieved, antimicrobial therapy is advised for 7 days. Within this window, improvement of clinical signs of infection should be used to judge the termination point for antimicrobial therapy. ¹⁸
Gram negative bacillus (GNB) bacteremia	7 days	1 systematic review ²⁵ 3 recent RCTs (N =1,186) ¹ 2 observational studies ^{20,25}	No difference in mortality between groups ^{19,20,21}	No difference in prolonged hospitalization ²⁴	No difference in occurrence of therapeutic failure between groups ²²	No difference in recurrence or readmission rate between groups ^{23,25,26}	No difference in adverse events between groups ²³	IDSA recommendations on durations of therapy are not provided, but clinicians are advised that prolonged treatment courses are not necessary for infections caused by antimicrobial resistant pathogens per se, compared to infections caused by the same bacterial species with a more susceptible phenotype.** Evidence supports 7 days of antimicrobial therapy for patients with uncomplicated GNB bacteremia with a known source. ²¹⁻²⁶
Complex appendicitis	1-2 days	2 RCTs (N=1,085) ¹	No difference in mortality ³¹	Reduced hospital length of stay ³²	No difference in clinical improvements	No difference in surgical site infections ³¹	Fewer adverse events in short-course group ³¹	Evidence supports that for complex appendicitis (appendicitis with necrosis, perforation or abscess) short course of postoperative antibiotics for 1-2 days is equally as effective as long postoperative antibiotics courses (5 days). While one RCT showed no difference in readmission ³² and the other showed higher readmission, it is important to note that it is difficult to be readmitted when you are in the hospital for longer duration.
Acute bacterial rhinosinusitis (ABRS)	3-7 days depending on the antibiotics used	6 RCTs (N=2423) ¹	<i>Limited/insufficient data</i>	<i>Limited/insufficient data</i>	No difference in efficacy ^{27,28}	No difference in recurrence ²⁸	Fewer adverse events in short-course group ^{27,28}	Clinicians do not necessarily need to use antibiotics for ABRS. ^{29,30} Antimicrobial therapy for Acute Bacterial Rhinosinusitis Guidelines ^{29,30} found no difference in outcomes based on antibiotics used. If used, duration depends on the class of antibiotics and should be limited to 3-7 days, e.g. 3 days for TMP-SMX ²⁸ or azithromycin ²⁷ , 5 days for respiratory fluoroquinolones, and 5-7 days for amoxicillin/clavulanate. ^{29,30}

*Direct recommendation from American College of Physicians (ACP) Guidelines

**Direct recommendation from the Infectious Diseases Society of America (IDSA)

Condition	Short duration	Available evidence	Mortality	Length of stay	Clinical success rate	Relapse rate	Adverse events	Tufts Medical Center Antimicrobial Stewardship Team Advice
Empyema	14-21 days	2 RCTs (N=105) ^{34,35}	No data available	No data available	No difference in treatment failure or clinical success between groups ^{34,35}	No difference in persistent symptoms at 6 weeks ³⁴	No difference between groups ^{34,35}	Shorter course is recommended for patients for first case of pleural infection and clinical improvement within 14 days. Oral therapy is recommended. ^{34,35}
Septic arthritis of hand and wrist native joints	14 days	1 RCT (N=154) ³⁶	No data available	No data available	No difference in clinical remission	No difference in recurrence ³⁶	No difference in antibiotic ADE or neurologic or mechanical sequelae ³⁶	Patients underwent drainage of joints as part of clinical management. Oral therapy recommended as step down. ³⁶
Variceal bleed	3 day	1 RCT (N=71) ³⁷	No difference in 28 day survival	No data available	No difference in rebleeding rate ³⁷	No difference in transfusion amount ³⁷	<i>Limited/insufficient data</i>	Infection in cirrhotic patients with variceal bleed will most likely occur within 48 hours. ³⁸

*Direct recommendation from American College of Physicians (ACP) Guidelines

**Direct recommendation from the Infectious Diseases Society of America (IDSA)

Compiled from ACP and other literature

- 1 Lee RA, Centor RM, Humphrey LL, Jokela JA, Andrews R, Qaseem A. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians. *Ann Intern Med.* 2021 Apr 6. doi: 10.7326/M20-7355. Epub ahead of print. PMID: 33819054.
- 2 Mohamed Amine M, Selma M, Adel S, Khaoula BHA, Mohamed Hassene K, Imen T, Ahmed A, Nadia BB, Yosra BD, Rabie R, Mohamed Habib G, Kaouthar B, Mehdi M, Asma B, Wahid B, Riadh B, Hamdi B, Semir N; GREAT Network. 2-Day versus C-reactive protein guided antibiotherapy with levofloxacin in acute COPD exacerbation: A randomized controlled trial. *PLoS One.* 2021 May 20;16(5):e0251716. doi: 10.1371/journal.pone.0251716. Erratum in: *PLoS One.* 2021 Jun 9;16(6):e0253252. PMID: 34015041; PMCID: PMC8136675.
- 3 Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. *Am J Respir Crit Care Med* 2000; 162(2 Pt 1): 505-11.
- 4 Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. *Current medical research and opinion* 2004; 20(4): 555-63.
- 5 Ginsburg AS, Mvalo T, Nkwopara E. et al. Amoxicillin for 3 or 5 Days for Chest-Indrawing Pneumonia in Malawian Children. *NEJM.* 2020 383: 13-23.
- 6 Eliakim-Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother.* 2013 Oct;68(10):2183-91. doi: 10.1093/jac/dkt177. Epub 2013 May 21. PMID: 23696620.
- 7 Klausner HA, Brown P, Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. *Curr Med Res Opin.* 2007 Nov;23(11):2637-45. doi: 10.1185/030079907x233340. PMID: 17880755.
- 8 Erba L, Furlan L, Monti A, Marsala E, Cernuschi G, Solbiati M, Bracco C, Bandini G, Pecorino Meli M, Casazza G, Montano N, Sbrojavacca R, Costantino G. Short vs long-course antibiotic therapy in pyelonephritis: a comparison of systematic reviews and guidelines for the SIMI choosing wisely campaign. *Intern Emerg Med.* 2021 Mar;16(2):313-323. doi: 10.1007/s11739-020-02401-4. Epub 2020 Jun 21. PMID: 32566969.
- 9 Eliakim-Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother.* 2013 Oct;68(10):2183-91. doi: 10.1093/jac/dkt177. Epub 2013 May 21. PMID: 23696620.
- 10 Klausner HA, Brown P, Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. *Curr Med Res Opin.* 2007 Nov;23(11):2637-45. doi: 10.1185/030079907x233340. PMID: 17880755.
- 11 Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis.* 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5. PMID: 24909499.
- 12 Andre C. Kalil, Mark L. Metersky, Michael Klompas, John Muscedere, Daniel A. Sweeney, Lucy B. Palmer, Lena M. Napolitano, Naomi P. O'Grady, John G. Bartlett, Jordi Carratalà, Ali A. El Solh, Santiago Ewig, Paul D. Fey, Thomas M. File, Jr, Marcos I. Restrepo, Jason A. Roberts, Grant W. Waterer, Peggy Cruse, Shandra L. Knight, Jan L. Brozek, Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society, *Clinical Infectious Diseases*, Volume 63, Issue 5, 1 September 2016, Pages e61–e111, <https://doi.org/10.1093/cid/ciw353>
- 13 Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. *JAMA : the journal of the American Medical Association* 2003; 290(19): 2588-98.
- 14 Capellier G, Mockly H, Charpentier C, et al. Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. *PLoS One* 2012; 7(8): e41290.
- 15 Metersky ML, Kalil AC. Management of Ventilator-Associated Pneumonia: Guidelines. *Clin Chest Med.* 2018 Dec;39(4):797-808. doi: 10.1016/j.ccm.2018.08.002. PMID: 30390750.
- 16 Smith SE, Rumbaugh KA, May AK. Evaluation of a Short Course of Antimicrobial Therapy for Complicated Intra-Abdominal Infections in Critically Ill Surgical Patients. *Surg Infect (Larchmt).* 2017 Aug/Sep;18(6):742-750. doi: 10.1089/sur.2017.011. PMID: 28832270.
- 17 Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. *N Engl J Med* 2015; 372(21): 1996-2005.
- 18 Hedrick TL, Evans HL, Smith RL, McElearney ST, Schulman AS, Chong TW, Pruett TL, Sawyer RG. Can we define the ideal duration of antibiotic therapy? *Surg Infect (Larchmt).* 2006 Oct;7(5):419-32. doi: 10.1089/sur.2006.7.419. PMID: 17083308.
- 19 Yahav D, Franceschini E, Koppel F, et al. Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial. *Clin Infect Dis* 2018 69:1091-8.
- 20 von Dach E, Albrich WC, Brunel AS, et al. Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial. *JAMA.* 2020. 323:2160-9.

- 21 Sousa A, Pérez-Rodríguez MT, Suárez M, Val N, Martínez-Lamas L, Nodar A, Longueira R, Crespo M. Short- versus long-course therapy in gram-negative bacilli bloodstream infections. *Eur J Clin Microbiol Infect Dis*. 2019 May;38(5):851-857. doi: 10.1007/s10096-019-03467-5. Epub 2019 Jan 24. PMID: 30680566.
- 22 Ruiz-Ruigómez M, Fernández-Ruiz M, San-Juan R, López-Medrano F, Orellana MÁ, Corbella L, Rodríguez-Goncer I, Hernández Jiménez P, Aguado JM. Impact of duration of antibiotic therapy in central venous catheter-related bloodstream infection due to Gram-negative bacilli. *J Antimicrob Chemother*. 2020 Oct 1;75(10):3049-3055. doi: 10.1093/jac/dkaa244. PMID: 32591804.
- 23 Pranita D, Tamma*, Samuel L, Aitken, Robert A, Bonomo, Amy J, Mathers, David van Duin, Cornelius J, Clancy, Infectious Diseases Society of America Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections, 8 September 2020, <https://www.idsociety.org/practice-guideline/amr-guidance/>
- 24 Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, Neuberger A, Ghanem-Zoubi N, Santoro A, Eliakim-Raz N, Pertzov B, Steinmetz T, Stern A, Dickstein Y, Maroun E, Zayyad H, Bishara J, Alon D, Edel Y, Goldberg E, Venturelli C, Mussini C, Leibovici L, Paul M; Bacteremia Duration Study Group. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. *Clin Infect Dis*. 2019 Sep 13;69(7):1091-1098.
- 25 El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. *Thorax* 2008; 63(5):415-22.
- 26 Messous S, Trabelsi I, Bel Haj Ali K, et al. Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial. *Ther Advanc Resp Dis*. 2022. 16:175.
- 27 Henry DC, Riffer E, Sokol WN, Chaudry NI, Swanson RN. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. *Antimicrob Agents Chemother*. 2003;47(9):2770-2774.
- 28 Williams JW Jr, Holleman DR Jr, Samsa GP, Simel DL. Randomized controlled trial of 3 vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis. *JAMA*. 1995;273(13):1015-1021.
- 29 Rosenfeld, R.M., Piccirillo, J.F., Chandrasekhar, S.S., Brook, I., Ashok Kumar, K., Kramper, M., Orlandi, R.R., Palmer, J.N., Patel, Z.M., Peters, A., Walsh, S.A. and Corrigan, M.D. (2015), Clinical Practice Guideline (Update): Adult Sinusitis. *Otolaryngology-Head and Neck Surgery*, 152: S1-S39. <https://doi.org/10.1177/0194599815572097>
- 30 Anthony W. Chow, Michael S. Benninger, Itzhak Brook, Jan L. Brozek, Ellie J. C. Goldstein, Lauri A. Hicks, George A. Pankey, Mitchel Seleznick, Gregory Volturo, Ellen R. Wald, Thomas M. File, IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults, *Clinical Infectious Diseases*, Volume 54, Issue 8, 15 April 2012, Pages e72–e112, <https://doi.org/10.1093/cid/cis370>
- 31 de Wijkerslooth E, Boerma EJJ, van Rossem CC, et al. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, noninferiority randomised trial. *Lancet*. 2023.
- 32 Saar S, Mihnovits V, Lustenberger T, et al. Twenty-four hour versus extended antibiotic administration after surgery in complicated appendicitis: A randomized controlled trial. *J Trauma Acute Care Surg*. 2019. 86:36-42.
- 33 Gariani K, Pham T-T, Kressman B, et al. Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trial. *Clin Infect Dis* 2021. 73(7):e1539-e1545.
- 34 Hassan M, Gad-Allah M, El-Shaarawy B, et al. The Short versus Long Antibiotic Course for Pleural Infection Management (SLIM) randomised controlled open-label trial. *ERJ Open Res*. 2023 Apr 11;9(2):00635-2022.
- 35 Porcel JM, Ferreira L, Rumi L, et al. Two vs. three weeks of treatment with amoxicillin-clavulanate for stabilized community-acquired complicated parapneumonic effusions. A preliminary non-inferiority, double-blind, randomized, controlled trial. *Pleura Peritoneum*. 2020 Feb 26;5(1):20190027.
- 36 Gjika E, et al. Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial. *Ann Rheum Dis* 2019; 78:1114-1121.
- 37 Lee TH, Huang CT, Lin CC, Chung CS, Lin CK, Tsai KC. Similar rebleeding rate in 3-day and 7-day intravenous ceftriaxone prophylaxis for patients with acute variceal bleeding. *J Formos Med Assoc*. 2016 Jul;115(7):547-52. doi: 10.1016/j.jfma.2016.01.006. Epub 2016 Feb 15. PMID: 26899745.
- 38 Bernard B., Cadranet J.F., Valla D., Escolano S., Jarlier V., Opolon P.: Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. *Gastroenterology* 1995; 108: pp. 1828-1834.
- 39 Trautner BW, Cortés-Penfield NW, Gupta K, Hirsch EB, Horstman M, Moran GJ, Colgan R, O'Horo JC, Ashraf MS, Connolly S, Drekonja D, Grigoryan L, Huttner A, Lazenby GB, Nicolle L, Schaeffer A, Yawetz S, Lavergne V. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Duration of Antibiotics for Complicated UTI. *Clin Infect Dis*. 2025 Dec 20:ciaf462. doi: 10.1093/cid/ciaf462. Epub ahead of print. PMID: 41419448.